Needham & Company Starts Neurocrine Bio. (NBIX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St edges up on AI enthusiasm, Mideast negotiation hopes
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices drop about 3% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- S&P 500 ends marginally lower as investors focus on US-Iran war
Neurocrine Biosciences (NBIX): Reiterating Overweight Ahead Of ASRM - Piper Jaffray
October 18, 2016 6:45 AM EDTPiper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Neurocrine Bio. (NASDAQ: NBIX) ahead of of Wednesdays presentations at ASRM.
The analyst reviewed the efficacy and safety results on elagolix and other GnRH antagonists in development. Based on... More
